Ignite Creation Date:
2025-12-26 @ 12:14 PM
Ignite Modification Date:
2026-02-24 @ 2:08 PM
Study NCT ID:
NCT02910700
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2025-12-17
First Post:
2016-09-20
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Nivolumab With Trametinib and Dabrafenib, or Encorafenib and Binimetinib in Treating Patients With BRAF Mutated Metastatic or Unresectable Stage III-IV Melanoma
Sponsor:
M.D. Anderson Cancer Center
Organization:
Organization Data
Organization:
Class:
OTHER
Study ID:
2015-0605
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
OTHER
Responsible Party:
Responsible Party Title:
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None
Collaborators
Collaborators
| Name | Class | View |
|---|---|---|
| None | NIH | View |